Hubungan Pemberian Estradiol Valerat 2 mg + Norgestrel 0,5 mg dengan Fungsi Kognitif yang Dinilai Berdasarkan Informant Questionnaire On Cognitive Decline In The Elderly (IQCODE) pada Paramedis Usia Menopause RSUP H.Adam Malik Medan

Abstract

Latar Belakang : Menopause adalah berhentinya menstruasi minimal 12 bulan, biasanya dimulai saat usia 45-50 tahun serta disertai menurunnya hormon estrogen dan progesteron, sehingga menimbulkan keluhan salah satunya yaitu penurunan fungsi kognitif. Terapi sulih hormon seperti estradiol valerate dan norgestrel dapat mengurangi keluhan serta mengurangi risiko demensia. Tujuan : Menilai perbedaan fungsi kognitif dengan pemberian estradiol valerate 2 mg dan norgestrel 0,5 mg yang dinilai berdasarkan IQCODE pada paramedis yang menopause. Metode : Penelitian ini merupakan penelitian quasi eksperimental dengan rancangan pre post design yang dilakukan pada bulan Juli-Desember 2017. Subjek penelitian merupakan paramedis yang menopause di RSUP H.Adam Malik berjumlah 40 orang dan dipilih secara consecutive sampling. Subjek penelitian diminta untuk mengisi kuisioner IQCODE dan diesklusikan apabila hasilnya improvement dan no change. Subjek penelitian diminta untuk mengkonsumsi estradiol valerate 2 mg dan norgestrel 0,5 mg selama 3 bulan kemudian fungsi kognitif dinilai kembali. Analisis data menggunakan uji T berpasangan. Hasil : Dari 40 orang subjek penelitian, 2 orang memiliki kategori improvement dan no change dan 2 orang lainnya diekslusikan karena takikardia dan loss to follow up. Karakteristik subjek penelitian yang paling banyak dijumpai adalah kelompok usia 50-59 tahun (72,2%), multipara (91,7%), overweight (63,9%) dengan lama menopause 2 tahun (36,1%). Rerata skor IQCODE sebelum dan setelah intervensi berturut-turut adalah 3,59 ± 0,26 dan 3,18 ± 0,29 serta terdapat hubungan antara pemberian estradiol valerate dan norgestrel dengan fungsi kognitif. Kesimpulan : Adanya hubungan antara pemberian estradiol valerate 2 mg dan norgestrel 0,5 mg dengan fungsi kognitif (p < 0,05).

Background : Menopause is the cessation of menstruation at least 12 months, begins at the age of 45-50 years and accompanied by the declined of estrogen and progesterone hormones, causing complaints such as the decline in cognitive function. Hormone replacement therapy such as estradiol valerate and norgestrel can reduce complaints and reduce the risk of dementia. Objective : To assessed the difference in cognitive function with the administration of estradiol valerate 2 mg and norgestrel 0,5 mg which assessed by IQCODE on menopausal paramedics. Methods : This study is an experimental quasi research with pre-post design conducted in July-December 2017. The study subjects were 40 menopausal paramedics at H.Adam Malik General Hospital and selected by consecutive sampling. Study subjects were asked to fill out the IQCODE questionnaire and will be excluded if the result is improvement and no change. Study subjects were asked to consume estradiol valerate 2 mg and norgestrel 0.5 mg for 3 months then cognitive function will be revalued. Data were analyzed using T-paired test. Results : Out of the 40 study subjects, 2 had improvement and no change, while the other 2 subjects were excluded due to tachycardia and loss to follow up. The most often encountered characteristics of study subjects were the 50-59 years group (72.2%), multiparous (91.7%), overweight (63.9%) with duration of menopause for 2 years (36.1%). The mean score of IQCODE before and after intervention was 3.59 ± 0.26 and 3.18 ± 0.29 and there was a relationship between administering estradiol valerate and norgestrel with cognitive function. Conclusion : There was a significant association between administering estradiol valerate 2 mg and norgestrel 0.5 mg with cognitive function (p < 0,05).